Posts

Gilead's Trodelvy Broad FDA Approval in Front-Line TNBC Fuels TROP2 ADC Market War

on

Globalisation 2.0 | Henlius Completes First Patient Dosed in China for MRCT of pimurutamab (HLX07) Plus serplulimab, Accelerating Global Development

on

Bayer Receives Breakthrough Therapy Designation in US and China for Sevabertinib in First-Line HER2-Mutant NSCLC

on

Bayer Receives Breakthrough Therapy Designation in US and China for Sevabertinib in First-Line HER2-Mutant NSCLC

on

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

on

Eli Lilly’s Jaypirca pushes into first-line CLL, but commercial upside may be limited

on

Eli Lilly Touts 'Striking' Progression-Free Survival Results for Jaypirca in New Front-Line CLL Study

on

AstraZeneca's Calquence Combo Approved for First-Line CLL in EU

on